{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699995540526208.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1212/01.wnl.0000159399.81861.d5"}},{"identifier":{"@type":"URI","@value":"https://www.neurology.org/doi/pdfdirect/10.1212/01.WNL.0000159399.81861.D5"}}],"dc:title":[{"@value":"An open label study of the effects of rituximab in neuromyelitis optica"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699995540526208","@type":"Researcher","foaf:name":[{"@value":"B. A.C. Cree"}],"jpcoar:affiliationName":[{"@value":"From University of California, San Francisco."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995540526210","@type":"Researcher","foaf:name":[{"@value":"S. Lamb"}],"jpcoar:affiliationName":[{"@value":"From University of California, San Francisco."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995540526336","@type":"Researcher","foaf:name":[{"@value":"K. Morgan"}],"jpcoar:affiliationName":[{"@value":"From University of California, San Francisco."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995540526337","@type":"Researcher","foaf:name":[{"@value":"A. Chen"}],"jpcoar:affiliationName":[{"@value":"From University of California, San Francisco."}]},{"@id":"https://cir.nii.ac.jp/crid/1381699995540526209","@type":"Researcher","foaf:name":[{"@value":"E. Waubant"}],"jpcoar:affiliationName":[{"@value":"From University of California, San Francisco."}]},{"@id":"https://cir.nii.ac.jp/crid/1380004238112660363","@type":"Researcher","foaf:name":[{"@value":"C. Genain"}],"jpcoar:affiliationName":[{"@value":"From University of California, San Francisco."}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00283878"},{"@type":"EISSN","@value":"1526632X"},{"@type":"PISSN","@value":"https://id.crossref.org/issn/00283878"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/00283878"}],"prism:publicationName":[{"@value":"Neurology"}],"dc:publisher":[{"@value":"Ovid Technologies (Wolters Kluwer Health)"}],"prism:publicationDate":"2005-04-12","prism:volume":"64","prism:number":"7","prism:startingPage":"1270","prism:endingPage":"1272"},"reviewed":"false","url":[{"@id":"https://www.neurology.org/doi/pdfdirect/10.1212/01.WNL.0000159399.81861.D5"}],"createdAt":"2011-06-14","modifiedAt":"2024-03-28","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050294045368925696","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Efficacy for the Annual Relapse Rate after the Immunosuppressive Therapy in Patients Associated with Anti-AQP4 or Anti-MOG Antibody-Positive Optic Neuritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004239450312960","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565169025915008","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Challenges and opportunities in designing clinical trials for neuromyelitis optica"}]},{"@id":"https://cir.nii.ac.jp/crid/1360572092858758784","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584340724030976","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term Effects of IL-6 Receptor Blockade Therapy on Regulatory Lymphocytes and Neutrophils in Neuromyelitis Optica Spectrum Disorder"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846641013516928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Treatment of neuromyelitis optica: Review and recommendations"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846642061385344","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846643074893696","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The Pathology of an Autoimmune Astrocytopathy: Lessons Learned from Neuromyelitis Optica"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567424830336","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1360857701217212672","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration"}]},{"@id":"https://cir.nii.ac.jp/crid/1361412892426168192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205036507136","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Treatment of NMO"},{"@language":"ja","@value":"シンポジウム８‐４　Ｎｅｕｒｏｍｙｅｌｉｔｉｓ　Ｏｐｔｉｃａ（ＮＭＯ）　視神経脊髄炎（ＮＭＯ）の治療"},{"@value":"視神経脊髄炎(NMO)の治療"},{"@language":"ja-Kana","@value":"シシンケイ セキズイエン NMO ノ チリョウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206445154688","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"7. Clinical Guidelines for Neurological Disease."},{"@language":"ja","@value":"7．神経・筋"},{"@value":"神経・筋"},{"@language":"ja-Kana","@value":"シンケイ キン"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679216071424","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Establishment of a New Sensitive Assay for Anti-Human Aquaporin-4 Antibody in Neuromyelitis Optica"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679622349952","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"地域在住の難治性疼痛患者に対する聴覚ニューロフィードバックトレーニングの効果"},{"@language":"en","@value":"Effects of Auditory Neuro-feedback Training on a Community-dwelling Patient with Intractable-pain"},{"@language":"ja-Kana","@value":"チイキ ザイジュウ ノ ナンチセイ トウツウ カンジャ ニ タイスル チョウカク ニューロフィードバックトレーニング ノ コウカ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680011228928","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Trial of rituximab in three patients with neuromyelitis optica"},{"@language":"ja","@value":"Ｎｅｕｒｏｍｙｅｌｉｔｉｓ　ｏｐｔｉｃａへのＲｉｔｕｘｉｍａｂ治療の試み"},{"@language":"ja-Kana","@value":"Neuromyelitis optica エ ノ Rituximab チリョウ ノ ココロミ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680012313856","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Neuromyelitis optica"},{"@value":"視神経脊髄炎"}]},{"@id":"https://cir.nii.ac.jp/crid/1390574500939679616","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"II. Neuromyelitis Optica Spectrum Disorder"},{"@language":"ja","@value":"II．視神経脊髄炎スペクトラム障害"}]},{"@id":"https://cir.nii.ac.jp/crid/1390870297797552128","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1212/01.wnl.0000159399.81861.d5"},{"@type":"CROSSREF","@value":"10.1620/tjem.210.307_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.3389/fneur.2018.00888_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.2169/naika.99.3005_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.5692/clinicalneurol.49.457_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.2169/naika.110.1568_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.1212/wnl.0000000000001520_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.1155/2020/8871146_references_DOI_RDPmCTuDdMhXlab1FD267BEYQeN"},{"@type":"CROSSREF","@value":"10.1016/s1474-4422(20)30066-1_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.1212/nxi.0000000000200173_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.6772-25_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.1073/pnas.1017385108_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.1111/bpa.12099_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.5692/clinicalneurol.52.1231_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.1589/rika.30.759_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.1016/j.msard.2020.102251_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.1016/j.msard.2022.103730_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.1016/s0140-6736(19)31817-3_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.1016/j.msard.2012.06.002_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"},{"@type":"CROSSREF","@value":"10.5692/clinicalneurol.49.902_references_DOI_I6VKXXOdJwsSXoNaIAqropZmKyY"}]}